Bristol-Myers Squibb Co. (BMY)

47.10
0.79 1.71
NYSE : Health Technology
Prev Close 46.31
Open 46.55
Day Low/High 46.48 / 47.15
52 Wk Low/High 44.30 / 63.69
Volume 5.47M
Avg Volume 18.61M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 76.63B
EPS 3.00
P/E Ratio 14.92
Div & Yield 1.64 (3.44%)

Latest News

Rally With a Twist: Cramer's 'Mad Money' Recap (Wednesday 5/15/19)

Rally With a Twist: Cramer's 'Mad Money' Recap (Wednesday 5/15/19)

Jim Cramer says this market is influenced by tariffs and trade talks -- with the Federal Reserve and the economy playing second fiddle.

Applied Materials, HP, Lam Research: 'Mad Money' Lightning Round

Applied Materials, HP, Lam Research: 'Mad Money' Lightning Round

Jim Cramer takes a look at Applied Materials, HP, Lam Research, Schlumberger, PBF Energy, Targa Resources, Mallinckrodt and more.

Survivorship Today: What It's Like To Live With Cancer

Survivorship Today: What It's Like To Live With Cancer

Two-time Emmy Award winner Sterling K. Brown ( This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis.

Bristol-Myers Squibb To Take Part In The UBS Global Healthcare Conference

Bristol-Myers Squibb To Take Part In The UBS Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, in New York.

Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint Of Overall Survival With Opdivo (nivolumab) Plus Radiation In Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint Of Overall Survival With Opdivo (nivolumab) Plus Radiation In Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Bristol-Myers Squibb Company (NYSE: BMY) today announced the Phase 3 CheckMate -498 trial evaluating Opdivo (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase...

Bristol-Myers Squibb Company Prices $19 Billion Of Senior Unsecured Notes

Bristol-Myers Squibb Company Prices $19 Billion Of Senior Unsecured Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") today announced that it priced its previously announced private offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $19 billion (collectively, the...

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.

Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet

Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet

As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.

What to Watch Out For: Cramer's 'Mad Money' Recap (Thursday 5/2/19)

What to Watch Out For: Cramer's 'Mad Money' Recap (Thursday 5/2/19)

Jim Cramer says that although a sell-off can breed a buying opportunity, investors need to worry about sky-high IPOs and other signs of froth.

Shake It All Out

Nothing’s wrong with a market correction – the Russell 2000 even outperformed – but keep your eyes on the declining McClellan Summation Index.

Bristol-Myers Squibb Company Announces Results Of Early Participation In Exchange Offers And Consent Solicitations For Celgene Corporation Notes

Bristol-Myers Squibb Company Announces Results Of Early Participation In Exchange Offers And Consent Solicitations For Celgene Corporation Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today that the requisite number of consents have been received to adopt proposed amendments with respect to all outstanding notes of Celgene Corporation (NASDAQ:CELG) ("Celgene").

Bristol-Myers Squibb Company Announces Launch Of Private Offering Of Senior Unsecured Notes

Bristol-Myers Squibb Company Announces Launch Of Private Offering Of Senior Unsecured Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") today announced that, subject to market and other conditions, it intends to commence a private offering (the "Offering") to sell senior unsecured notes (the "Notes").

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Analyzing this year's stock draft contest and individual stock-picking vs. indexing.

Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval

Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval

Bristol-Myers Squibb posted stronger than-expected first quarter earnings Thursday, and boosted one of its key profit forecast, after seeing off an activist challenge to its $74 billion takeover of cancer specialist Celgene earlier this month.

Stocks Edge Lower as Growth Concerns Resurface, Offsetting Solid US Earnings

Stocks Edge Lower as Growth Concerns Resurface, Offsetting Solid US Earnings

Global stocks pared gains Thursday, as weakening data and dovish central bank actions added to concerns over the pace of world growth and offset the bullish tenor from last night's after-the-bell earnings on Wall Street.

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robust operating performance across the portfolio.

Microsoft, Facebook, Tesla, Amazon and Deutsche Bank - 5 Things You Must Know

Microsoft, Facebook, Tesla, Amazon and Deutsche Bank - 5 Things You Must Know

U.S. stock futures trade mixed on Thursday; Amazon, Intel and Comcast report earnings; Microsoft jumps as third-quarter earnings beat analysts' expectations; Facebook sets aside $3 billion for expected fine from Federal Trade Commission.

Bristol-Myers Squibb Expected to Earn $1.09 a Share

Bristol-Myers Squibb Expected to Earn $1.09 a Share

Bristol-Myers Squibb revenue expected to rise 10.8% to $5.8 billion.

Bristol-Myers Squibb Company Announces Commencement Of Exchange Offers And Consent Solicitations For Celgene Notes

Bristol-Myers Squibb Company Announces Commencement Of Exchange Offers And Consent Solicitations For Celgene Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb) announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation (NASDAQ:CELG) ("Celgene") , of an exchange offer for any and all outstanding...

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition

Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company's pending merger with Celgene Corporation (NASDAQ:CELG) at the...

Bristol-Myers Squibb Announces Long-Term Survival Results From Pooled Analyses Of Opdivo (nivolumab) In Previously-Treated Non-Small Cell Lung Cancer Patients

Bristol-Myers Squibb Announces Long-Term Survival Results From Pooled Analyses Of Opdivo (nivolumab) In Previously-Treated Non-Small Cell Lung Cancer Patients

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were...

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.

Bristol-Myers Squibb Issues Statement On Celgene's Settlement With Alvogen On Revlimid® Patent Litigation

Bristol-Myers Squibb Issues Statement On Celgene's Settlement With Alvogen On Revlimid® Patent Litigation

Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene's (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co.

Starboard Issues Statement On Bristol-Myers

Starboard Issues Statement On Bristol-Myers

NEW YORK, March 29, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), a shareholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY), today provided the following statement on its investment...

TheStreet Quant Rating: C+ (Hold)